Sparc Life
Jaydeep Issrani is an accomplished professional with extensive experience in business development, corporate communication, and investor relations, currently serving as Senior General Manager at Sun Pharma Advanced Research Company Ltd. since August 2014. Prior roles at the same company include General Manager and Deputy General Manager in Business Development, as well as Senior Manager. Jaydeep's earlier career at Sanofi spanned from November 2006 to July 2014, with positions including Associate Director and Marketing Manager for the Oncology Business Unit, where digital initiatives were effectively led. Additional experience includes roles as Senior Product Manager and Product Manager in various capacities across Asia Pacific at Sanofi, and as Assistant Product Manager at Sun Pharmaceutical Industries Inc. and Business Development Executive at Ranbaxy. Jaydeep holds a PGDPM in Pharmaceutical Marketing and Management from SIES and a B. Pharm from the University of Mumbai.
This person is not in any teams
This person is not in any offices
Sparc Life
SPARC (NSE: SPARC; BSE: 532872) is a biopharmaceutical company continuously innovating new therapies in oncology, neurodegeneration, and immunology. SPARC's value proposition lies in our brick-and-mortar infrastructure to effectively translate therapies from the bench, through clinical studies, to regulatory approval. This engine has resulted in approval of two NDAs. Our approved products are marketed by our commercial partners in the US, China, and India. We are 400+ strong team spread across three global locations, with a vibrant research community of 350+ scientists working on a robust pipeline of clinical and preclinical programs. Our teams' strengths span the R&D spectrum: small and large molecule drug discovery; CMC development; preclinical translation (including NDA-enabling toxicology); and clinical development and operations. All of this makes SPARC unique among other small biopharma companies, especially single-asset or single-therapy focused companies. We continue to build and strengthen our innovation engine with emphases on strong scientific execution, high value analytics, and aggressive portfolio management, to redefine patient care in areas of unmet need.